147 related articles for article (PubMed ID: 7656502)
1. Clinical pharmacokinetics of altretamine.
Damia G; D'Incalci M
Clin Pharmacokinet; 1995 Jun; 28(6):439-48. PubMed ID: 7656502
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of solid-lipid-nanoparticles of altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and oral bioavailability.
Gidwani B; Vyas A
Int J Biol Macromol; 2017 Aug; 101():24-31. PubMed ID: 28315435
[TBL] [Abstract][Full Text] [Related]
3. The bioavailability of three altretamine formulations.
Runhaar EA; Neijt JP; Holthuis JJ; de Vos D
Pharm Weekbl Sci; 1989 Dec; 11(6):218-23. PubMed ID: 2515524
[TBL] [Abstract][Full Text] [Related]
4. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.
Ames MM; Richardson RL; Kovach JS; Moertel CG; O'Connell MJ
Cancer Res; 1990 Jan; 50(1):206-10. PubMed ID: 2104537
[TBL] [Abstract][Full Text] [Related]
5. Parenteral formulation of hexamethylmelamine potentially suitable for use in man.
Ames MM; Kovach JS
Cancer Treat Rep; 1982 Jul; 66(7):1579-81. PubMed ID: 6807543
[TBL] [Abstract][Full Text] [Related]
6. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
7. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR; Faulds D
Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
[TBL] [Abstract][Full Text] [Related]
8. Hexamethylmelamine and hexamethylmelamine hydrochloride.
van de Vaart-van Zutphen HP; Smulders CF; Renema J; Hulshoff A
Pharm Weekbl Sci; 1982 Apr; 4(2):25-31. PubMed ID: 6808457
[TBL] [Abstract][Full Text] [Related]
9. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation.
Sun J; Deng Y; Wang S; Cao J; Gao X; Dong X
Drug Deliv; 2010 Apr; 17(3):164-70. PubMed ID: 20196698
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.
Dubois J; Atassi G; Hanocq M; Abikhalil F
Cancer Chemother Pharmacol; 1988; 22(4):282-8. PubMed ID: 3139314
[TBL] [Abstract][Full Text] [Related]
11. Variable oral absorption of hexamethylmelamine in man.
D'Incalci M; Bolis G; Mangioni C; Morasca L; Garattini S
Cancer Treat Rep; 1978 Dec; 62(12):2117-9. PubMed ID: 109196
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of hexamethylmelamine in intralipid following hepatic regional administration in rabbits.
Gordon IL; Kar R; Opfell RW; Wile AG
Cancer Res; 1987 Oct; 47(19):5070-3. PubMed ID: 3113728
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Rustin GJ; Nelstrop AE; Crawford M; Ledermann J; Lambert HE; Coleman R; Johnson J; Evans H; Brown S; Oster W
J Clin Oncol; 1997 Jan; 15(1):172-6. PubMed ID: 8996139
[TBL] [Abstract][Full Text] [Related]
14. Low oral bioavailability of hexamethylmelamine in the rat due to simultaneous hepatic and intestinal metabolism.
Klippert PJ; Hulshoff A; Mingels MJ; Hofman G; Noordhoek J
Cancer Res; 1983 Jul; 43(7):3160-4. PubMed ID: 6406053
[TBL] [Abstract][Full Text] [Related]
15. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
Cumber AJ; Ross WC
Chem Biol Interact; 1977 Jun; 17(3):349-57. PubMed ID: 407012
[TBL] [Abstract][Full Text] [Related]
16. Hexamethylmelamine: pharmacology and mechanism of action.
Ames MM
Cancer Treat Rev; 1991 Mar; 18 Suppl A():3-14. PubMed ID: 1904306
[TBL] [Abstract][Full Text] [Related]
17. Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine.
Brindley C; Gescher A; Langdon SP; Broggini M; Colombo T; D'Incalci M
Biochem Pharmacol; 1982 Mar; 31(5):625-31. PubMed ID: 6805472
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs of hydroxymethylpentamethylmelamine: a principal active metabolite of the antineoplastic agent hexamethylmelamine.
Ghodrati F; Lavoie EJ
Drug Des Discov; 1994 Feb; 11(2):135-47. PubMed ID: 8075301
[TBL] [Abstract][Full Text] [Related]
19. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
Ames MM; Powis G; Kovach JS; Eagan RT
Cancer Res; 1979 Dec; 39(12):5016-21. PubMed ID: 115586
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of hexamethylmelamine administered via the Ip route in an oil emulsion vehicle.
Wickes AD; Howell SB
Cancer Treat Rep; 1985 Jun; 69(6):657-62. PubMed ID: 3926309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
